IRE1α inhibitor reduces cisplatin resistance in ovarian cancer by modulating IRE1α/XBP1 pathway
Cellular Oncology · 2024
DOI: 10.1007/s13402-024-01010-z ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Oncology, 2024. Verfasst von Shiyi Lv und 11 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, …. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Endoribonucleases, Cisplatin, Ovarian Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Shanghai Rising-Star Program, ECNU Construction Fund of Innovation and Entrepreneurship Laboratory.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China. huangchen9104@163.com.
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China. myliu@bio.ecnu.edu.cn.
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China. zfyi@bio.ecnu.edu.cn.
- Changning Maternity and Infant Health Hospital, East China Normal University, Shanghai, China. zfyi@bio.ecnu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Shanghai Rising-Star Program
- ECNU Construction Fund of Innovation and Entrepreneurship Laboratory
- The Jointed PI Program from Shanghai Changning Maternity and Infant Health Hospital and Changning District Health System (PI) Research Team Project Funding
Zitieren
APA
Lv, S., Zhang, L., Wu, M., Zhu, S., Wang, Y., Liu, L., Li, Y., Zhang, T., Wu, Y., Chen, H., Liu, M., & Yi, Z. (2024). IRE1α inhibitor reduces cisplatin resistance in ovarian cancer by modulating IRE1α/XBP1 pathway. Cellular Oncology. https://doi.org/10.1007/s13402-024-01010-z
Vancouver
Lv S, Zhang L, Wu M, Zhu S, Wang Y, Liu L, et al. IRE1α inhibitor reduces cisplatin resistance in ovarian cancer by modulating IRE1α/XBP1 pathway. Cellular Oncology. 2024. doi:10.1007/s13402-024-01010-z
BibTeX
@article{Lv2024,
author = {Lv, Shiyi and Zhang, Lin and Wu, Min and Zhu, Shuangshuang and Wang, Yixue and Liu, Layang and Li, Yunxuan and Zhang, Ting and Wu, Yujie and Chen, Huang and Liu, Mingyao and Yi, Zhengfang},
title = {IRE1α inhibitor reduces cisplatin resistance in ovarian cancer by modulating IRE1α/XBP1 pathway},
journal = {Cellular Oncology},
year = {2024},
doi = {10.1007/s13402-024-01010-z}
}
EUVIMED